Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy

Expert Review of Anticancer Therapy

Volumn 7, Issue 7, 2007, Pages 919-943

  Henderson, I Craig ^a   Bhatia, Vinona ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Chemotherapy; Cremophor; Docetaxel; Dose response; Nab paclitaxel; Nanoparticle; Neurotoxicity; Schedule response; Targeted therapy; Taxane

Indexed keywords

ALBUMIN; ANTHRACYCLINE DERIVATIVE; ANTIHISTAMINIC AGENT; CIMETIDINE; CORTICOSTEROID; CREMOPHOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ALOPECIA; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BLURRED VISION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG TUMOR LEVEL; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; DYSPNEA; EYE DISEASE; EYE TOXICITY; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; FLUSHING; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPOTENSION; INFECTION; KERATOPATHY; METASTASIS; MONOTHERAPY; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUROPATHIC PAIN; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; ONYCHOLYSIS; PARESTHESIA; PERIPHERAL EDEMA; SENSORIMOTOR NEUROPATHY; SENSORY NEUROPATHY; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SKIN TOXICITY; STOMATITIS; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; URTICARIA; VOMITING;

ALBUMINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS; HUMANS; PACLITAXEL;

EID: 34547515086     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.7.919     Document Type: Article

References (76)

1. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N. Engl. J. Med. 332(15), 1004-1014 (1995).
2. Windebank AJ, Blexrud MD, de Groen PC. Potential neurotoxicity of the solvent vehicle for cyclosporine. J. Pharmacol. Exp. Ther. 268(2), 1051-1056 (1994).
3. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F. Description of a short-term Taxol-induced nociceptive neuropathy in rats. Brain Res. 887(2), 239-249 (2000).
4. Colombo T, Parisi I, Zucchetti M, Sessa C, Goldhirsch A, D'Incalci M. Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin [see comments]. Ann. Oncol. 10(4), 391-395 (1999).
5. van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest. New Drugs 19(2), 125-141 (2001).
6. Soepenberg O, Sparreboom A, de Jonge MJ et al. Real-time pharmacokinetics guiding clinical decisions; Phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours. Eur. J. Cancer 40(5), 681-688 (2004).
7. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2(5), 347-360 (2003).
8. Garfield D. New form of paclitaxel shows promise. Lancet Oncol. 2(4), 192 (2001).
9. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int. J. Pharm. 235(1-2), 179-192 (2002).
10. Goodman LS, Gilman A. The Pharmacological Basis of Therapeutics. Macmillan Co., New York, NY, USA (1966).
11. Frei III EF, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am. J. Med. 69, 585-594 (1980).
12. Savarese DM, Hsieh C, Stewart FM. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J. Clin. Oncol. 15(8), 2981-2995 (1997).
13. Fassas A, Shaughnessy J, Barlogie B. Cure of myeloma: hype or reality? Bone Marrow Transplant. 35(3), 215-224 (2005).
14. Budman DR, Berry DA, Cirrincione CT et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J. Natl Cancer Inst. 90(16), 1205-1211 (1998).
15. Fisher B, Anderson S, Wickerham DL et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J. Clin. Oncol. 15(5), 1858-1869 (1997).
16. Fisher B, Anderson S, DeCillis A et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from national surgical adjuvant breast and bowel project B-25. J. Clin. Oncol. 17(11), 3374-3388 (1999).
17. Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. 21(6), 976-983 (2003).
18. HortobagyiGN, Buzdar AU, Theriault RL et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J. Natl Cancer Inst. 92(3), 225-233 (2000).
19. Stadtmauer EA, O'Neill A, Goldstein LJ et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N. Engl. J. Med. 342(15), 1069-1076 (2000).
20. Schrama JG, Faneyte IF, Schornagel JH et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann. Oncol. 13(5), 689-698 (2002).
21. Rodenhuis S, Bontenbal M, Beex LV et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N. Engl. J. Med. 349(1), 7-16 (2003).
22. Leonard RC, Lind M, Twelves C et al. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J. Natl Cancer Inst. 96(14), 1076-1083 (2004).
23. Zander AR, Kroger N, Schmoor C et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J. Clin. Oncol. 22(12), 2273-2283 (2004).
24. Coombes RC, Howell A, Emson M et al. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial. Ann. Oncol. 16(5), 726-734 (2005).
25. Nitz UA, Mohrmann S, Fischer J et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre Phase III trial. Lancet 366(9501), 1935-1944 (2005).
26. Peters WP, Rosner GL, Vredenburgh JJ et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J. Clin. Oncol. 23(10), 2191-2200 (2005).
27. Schmid P, Schippinger W, Nitsch T et al. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J. Clin. Oncol. 23(3), 432-440 (2005).
28. Winer EP, Berry DA, Woolf S et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J. Clin. Oncol. 22(11), 2061-2068 (2004).
29. Presant CA, Wolf W, Waluch V et al. Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet 343(8907), 1184-1187 (1994).
30. Muller M, Mader RM, Steiner B et al. 5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients. Cancer Res. 57(13), 2598-2601 (1997).
31. Muller M, Brunner M, Schmid R et al. Interstitial methotrexate kinetics in primary breast cancer lesions. Cancer Res. 58(14), 2982-2985. (1998).
32. Muller M, Bockenheimer J, Zellenberg U et al. Relationship between in vivo drug exposure of the tumor interstitium and inhibition of tumor cell growth in vitro: a study in breast cancer patients. Breast Cancer Res. Treat. 60(3), 211-217 (2000).
33. Robert NJ, Vogel CL, Henderson IC et al. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Semin. Oncol. 31(6 Suppl. 13), 106-146 (2004).
34. Sledge GW, Neuberg D, Bernardo P et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). J. Clin. Oncol. 21(4), 588-592 (2003).
35. Paridaens R, Biganzoli L, Bruning P et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over. J. Clin. Oncol. 18(4), 724-733 (2000).
36. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 21(8), 1431-1439 (2003).
37. Jones SE, Erban J, Overmoyer B et al. Randomized Phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J. Clin. Oncol. 23(24), 5542-5551 (2005).
38. Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. N. Engl. J. Med. 352(22), 2302-2313 (2005).
39. Roche H, Fumoleau P, Spielmann M et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J. Clin. Oncol. 24(36), 5664-5671 (2006).
40. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
41. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005).
42. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1659-1672 (2005).
43. Seidman A, Berry D, Cirrincione C et al. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc. Am. Soc. Clin. Oncol. 23, A512 (2004).
44. Tabernero J, Climent MA, Lluch A et al. A multicentre, randomised Phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann. Oncol. 15(9), 1358-1365 (2004).
45. Sparano JA, Wang M, Martino S et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. In: 28th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2005 (Abstract 48).
46. Brouwer E, Verweij J, De Bruijn P et al. Measurement of fraction unbound paclitaxel in human plasma. Drug Metab. Dispos. 28(10), 1141-1145 (2000).
47. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37(13), 1590-1598 (2001).
48. Webster L, Linsenmeyer M, Millward M, Morton C, Bishop J, Woodcock D. Measurement of cremophor EL following Taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J. Natl Cancer Inst. 85(20), 1685-1690 (1993).
49. Ibrahim NK, Desai N, Legha S et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 8(5), 1038-1044 (2002).
50. Sparreboom A, Scripture CD, Trieu V et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin. Cancer Res. 11(11), 4136-4143 (2005).
51. Desai N, Trieu V, Yao Z et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 12(4), 1317-1324 (2006).
52. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 6(4), 559-593 (1987).
53. Hobbs SK, Monsky WL, Yuan F et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl Acad. Sci. USA 95(8), 4607-4612 (1998).
54. Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 19(4 Suppl. 3), 7-16 (2005).
55. SchubertW, Frank PG, Razani B, Park DS, Chow CW, Lisanti MP. Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in vivo. J. Biol. Chem., 276(52), 48619-48622 (2001).
56. Watkins G, Douglas-Jones A, Bryce R, Mansel RE, Jiang WG. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot. Essent. Fatty Acids 72(4), 267-272 (2005).
57. Tai IT, Dai M, Owen DA, Chen LB. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J. Clin. Invest. 115(6), 1492-1502 (2005).
58. Shi Q, Bao S, Bigner D Jr. Secreted protein acidic and rich in cysteine (SPARC) activates focal adhesion kinase and integrin-linked kinase to induce AKT-dependent glioma survival and invasion. Presented at: 97th Annual Meeting of the American Association of Cancer Research (AACR), Washington, DC, USA, 1-5 April 2006 (17 Abstract 1683).
59. Desai N, Trieu V, Yao R, Frankel T, Soon-Shiong P. SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs taxol. Presented at: 26th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 3-6 December 2004 (Abstract 206).
60. Trieu V, Damascelli B, Soon-Shiong P, Desai N. SPARC expression in head and neck cancer correlates with tumor response to nanoparticle albumin-bound paclitaxel (nab paclitaxel, ABI-007, Abraxane). Presented at: 97th Annual Meeting of the American Association of Cancer Research (AACR). Washington, DC, USA, 1-5 April 2006 (17 Abstract 4477).
61. Nyman DW, Campbell KJ, Hersh E et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J. Clin. Oncol. 23(31), 7785-7793 (2005).
62. Sparreboom A, van Zuylen L, Brouwer E et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 59(7), 1454-1457 (1999).
63. Desai N, Trieu V, Yang A et al. Enhanced efficacy and safety of nanoparticle albumin-bound nab-docetaxel versus taxotere. Presented at: 97th Annual Meeting of the American Association of Cancer Research (AACR). Washington, DC, USA, 1-5 April 2006 (17 Abstract 5438).
64. Teng XY, Guan Z, Yao Z et al. A tolerability study of a cremophor-free, nanoparticle albumin bound paclitaxel intravenously administered in Chinese patients with advanced solid tumor. Proc. Am. Soc. Clin. Oncol. 24 (2005) (Abstract 5571).
65. Ibrahim NK, Samuels B, Page R et al. Multicenter Phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J. Clin. Oncol. 23(25), 6019-6026 (2005).
66. O'Shaughnessy JA, Blum JL, Sandbach JF, Savin M, Fenske E, Hawkins MJ. Weekly nanoparticle albumin paclitaxel (Abraxane) results in long-term disease control in patients with taxane-refractory metastatic breast cancer. In: 27th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004 (Abstract 1070).
67. Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23(31), 7794-7803 (2005).
68. Gradishar W, Krasnojon D, Cheporov S, Makhson A, Manikhas G, Hawkins MJ. A randomized Phase 2 trial of qw or q3w ABI-007 (ABX) vs. q3W solvent-based docetaxel (TXT) as first-line therapy in metastatic breast cancer (MBC). Presented at: 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 14-17 December 2006 (Abstract 46).
69. Hudis C, Citron M, Berry D et al. Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective. Presented at: 28th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2005 (Abstract 41).
70. Robert N, Ambro S, Krekow L et al. Pilot study of dose dense doxorubicin + cyclophosphamide followed by ABI-007 in patients with early stage breast cancer. Presented at: 28th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2005 (Abstract 2073).
71. Seidman AD, Danso M, Bach A et al. Phase II study of weekly nanoparticle paclitaxel (ABI-007), carboplatin and trastuzumab as first-line therapy of HER2-positive metastatic breast cancer. J. Clin. Oncol. (Meeting Abstracts), 24(18 Suppl.), (2006) (Abstract 10650).
72. Yardley DA, Meluch A, Murphy P et al. Preliminary results from a multicenter Phase II trial of biweekly neoadjuvant gemcitabine, epirubicin, ABI-007 (GEA) with correlative SPARC tumor analysis. Presented at: 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 14-17 December 2006 (Abstract 3069).
73. Moreno-Aspitia A, Perez EA. North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer. Clin. Breast Cancer 6(4), 361-364 (2005).
74. Link JS, Waisman JR, Jacobs CI. Bevacizumab (Avastin) and albumin bound paclitaxel (Abraxane) treatment in metastatic breast cancer. Presented at: 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 14-17 December 2006 (Abstract 1095).
75. Smith RE, Brown AM, Mamounas EP et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J. Clin. Oncol. 17(11), 3403-3411 (1999).
76. Abraxane®, Package Insert. Abraxis Oncology, a division of the American Pharmaceutical Partners, Inc. Schaumburg, IL, USA.